Biocon starts clinical study to evaluate efficacy of Itolizumab

This is a phase two randomised, double-blind, parallel-group, placebo and active-controlled (adalimumab), two treatment period study to evaluate the safety and efficacy of Itolizumab for the induction of remission in biologics naive patients with moderate to severely active Ulcerative Colitis (UC), Biocon said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d6vxPXh
via IFTTT